By Sheri Poe Bernard, CPC, COC, CCS-P I see a compliance fiasco waiting to happen in risk adjustment regarding tamoxifen and breast cancer coding. I was a minority of one regarding active breast cancer vs. history of breast cancer coding at a discussion during a recent HEALTHCON session, but I feel confident that I am ...
In Coding
Oct 1st, 2010
New dosage and administration technique recommendations for FASLODEX® were approved by the U.S. Food and Drug Administration (FDA) Sept. 10. New Dosing for FASLODEX Injections was last modified: July 5th, 2011 by admin aapc...